However, there were some approvals on the connection of polymorphism in XRCC2 R188H and the risk of breast cancer before, which has not been confirmed in two population studies in the United States and Poland and several case-control experimental studies (39, 42–44, 50, 51, 68). Here, XRCC2 is linked to breast carcinoma.